Advertisement
UK markets close in 8 hours 24 minutes

  • FTSE 100

    7,877.05
    0.00 (0.00%)
     

  • FTSE 250

    19,450.67
    0.00 (0.00%)
     

  • AIM

    745.29
    0.00 (0.00%)
     

  • GBP/EUR

    1.1675
    -0.0008 (-0.07%)
     

  • GBP/USD

    1.2435
    -0.0004 (-0.03%)
     

  • Bitcoin GBP

    52,175.59
    +2,967.39 (+6.03%)
     

  • CMC Crypto 200

    1,318.54
    +5.91 (+0.45%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CRUDE OIL

    83.90
    +1.17 (+1.41%)
     

  • GOLD FUTURES

    2,401.40
    +3.40 (+0.14%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,239.14
    -146.73 (-0.90%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • CAC 40

    8,023.26
    +41.75 (+0.52%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting

Sotio
·2-min read

PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting. The presentation focuses on preclinical data describing SOT102 which is intended for the treatment of CLDN18.2-expressing solid tumors.

SOT102 (earlier SO-N102) is a CLDN18.2 targeting antibody-drug conjugate based on a novel proprietary, highly-specific monoclonal antibody conjugated to a potent cytotoxic drug molecule exhibiting strong anti-tumor activity. SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin.

Poster Presentation details:

Title: SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels

ADVERTISEMENT

Poster Number: 1204

Session: PO.ET01.05 - New Targets

Presenting Author: Lenka Kyrych Sadilkova, Ph.D.

Date/ Time: Saturday, April 10, 2021 from 8:30 AM - 11:59 PM EST

Conference Registration Link: https://myaacr.aacr.org/LiveEventsList?ac__id=a4j1I000000Yd1r

A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes.

Company contact:

Media contact:

Richard Kapsa

Kirsten Frazer, Ph.D.

Head of Communication

LifeSci Communications

T: (+420) 224 174 448

T: +1 646-863-0222

M: (+420) 603 280 971

kfrazer@lifescicomms.com

kapsa@sotio.com

About SOTIO

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies, CAR T platform and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. For more information, please visit the company’s website at www.sotio.com.

SOTIO is a registered trademark of SOTIO a.s. in selected countries.